Spero Therapeutics (SPRO) Assets Average (2017 - 2026)
Spero Therapeutics' (SPRO) quarterly Assets Average came in at $64.0 million in Q1 2026, down 32.04% YoY from $94.1 million in Q1 2025, and up 3.94% on a QoQ basis from $61.5 million in Q4 2025.
Spero Therapeutics (SPRO) Assets Average (2017 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of Assets Average data on file, last reported at $64.0 million in Q1 2026.
- Quarterly Assets Average fell 32.04% year-over-year to $64.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.0 million (down 32.04% YoY) and the FY2025 annual result came in at $89.7 million, down 38.74% from the prior year.
- Assets Average climbed to $64.0 million in Q1 2026, from $61.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $175.0 million in Q1 2024 to a low of $58.1 million in Q3 2025.
- A 5-year average of $108.3 million and a median of $104.7 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average surged 60.8% — and 2025, when it plunged 59.2%.
- Tracing SPRO's Assets Average over 5 years: stood at $94.6 million in 2022, then jumped by 52.94% to $144.7 million in 2023, then retreated by 15.13% to $122.9 million in 2024, then sank by 49.9% to $61.5 million in 2025, then advanced by 3.94% to $64.0 million in 2026.
- The last three Assets Average figures came in at $64.0 million (Q1 2026), $61.5 million (Q4 2025), and $58.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 55.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.89 Mn |
| Mar 31, 2026 | 63.97 Mn |
| Dec 31, 2025 | 61.54 Mn |
| Sep 30, 2025 | 58.14 Mn |
| Jun 30, 2025 | 69.91 Mn |
| Mar 31, 2025 | 94.13 Mn |
| Dec 31, 2024 | 122.85 Mn |
| Sep 30, 2024 | 142.52 Mn |
| Jun 30, 2024 | 158.79 Mn |
| Mar 31, 2024 | 175.05 Mn |
| Dec 31, 2023 | 144.75 Mn |
| Sep 30, 2023 | 102.99 Mn |
| Jun 30, 2023 | 105.72 Mn |
| Mar 31, 2023 | 118.67 Mn |
| Dec 31, 2022 | 94.64 Mn |
| Sep 30, 2022 | 64.05 Mn |
| Jun 30, 2022 | 104.73 Mn |
| Mar 31, 2022 | 158.45 Mn |
| Dec 31, 2021 | 157.88 Mn |
| Sep 30, 2021 | 132.14 Mn |